Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose open-label mass balance and pharmacokinetic study of radiolabeled RO6868847 in healthy men
NL-OMON51247Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vicasinabin in diabetic retinopathy (DR), sponsored by Roche. Primary endpoints: Mass balance and routes of elimination and Pharmacokinetics of radioactivity, parent drug, and metabolites. Started Mar 2021; status: completed.
02
Drugs
vicasinabin
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NL-OMON51247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51247.